AnaptysBio Swings to $3.9M Q3 Profit on $30.3M Collaboration Revenue
ANAB has more than doubled off its 52-week low of $21.93.
Summary
AnaptysBio posted Q3 net income of $3.876 million, with income from operations of $19.905 million. Collaboration revenue came in at $30.274 million against operating expenses of just $10.369 million, so the quarter was driven by revenue far outpacing a lean cost base. That is a sharp contrast to Q2, when the company reported $177.3 million of net income almost entirely from a $181.5 million non-cash tax benefit rather than operations. The operating profit here is the more meaningful number for the underlying business. Watch the Delaware Chancery litigation over the contract breach claim, where a hearing began October 20 and shares fell 8% that day.
At the time of this announcement, ANAB was trading at $47.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $21.93 to $72.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.